This paper presented a risk factor probability comprehensive evaluation model which considers historical data as well as the experts' analysis of the object system in recent years, namely, the risk factor probability evaluation model based on information revision, and employed for risk evaluation of the city gas transmission and distribution system with a case study.
One mechanism for addressing these expectations is voluntary development of a uniform national registry for joint replacements that includes capture of preoperative appropriateness indicators, device monitoring information, revision rates, and structured postoperative patient followup.
However, this nationwide registry was suspended because of several issues such as the operation of the Act Concerning Protection of Personal Information, revision of the JGCA classification for gastric cancer, and rapid changes in the information technology (IT) environment at the member hospitals.
Similarly, the only published information on revision rates in the United States provides the proportion of annual procedures performed as revisions, rather than a Kaplan-Meier estimate of cumulative revision rates.
Information on revision due to PJI was collected from the DHR (using deep infection as indication for revision) and the NRP (using the diagnosis DT845*, "infection or inflammation in the area of a prosthesis" in combination with one of the surgical procedure codes for revision described above).
When analysing time to death, we censored those patients alive or revised at the end of their follow-up; follow-up information after revision was not available in the database.
From the NAR, data on patient demographics (Table 2), diagnosis, type of prosthesis, date of surgery, and information on revision surgery were collected.
The main aim of the present study was to identify microbiologic and patient-related criteria differentiating HUS STEC from non-HUS STEC, in order to obtain information enabling revision of the strict control and prevention measures presently employed in Norway.
Under the EU Directive and the Clinical Trials Regulations, a REC must give an opinion on a clinical trial within 60 days of receipt of a valid application and should reach one of four possible decisions: 'Final opinion' favourable or unfavourable; 'Provisional opinion' (with further information or revision required) or 'No opinion' (a referee needs to be consulted before an opinion can be given).
Our complete FU, our detailed information on revision cases and the excellent clinical scores at the time of final FU are in contrast to other designs of HRA, of which failure rates of 25% for ARMD after six years FU are reported [ 21].
